Powder For Suspension Stafoxin 125 mg/5 ml - 100 ml
৳ 60
Quantity:
1
Order By Call:
+88 01540 384 786 (Mobile)
+88 01819 479 004 (WhatsApp)
Payment Methods
About the Product
Full Description
\n
\n
\n \n
\n \n
\n \n
\nSilodosin is a selective antagonist of post-synaptic alpha-1 adrenoreceptors, which are located in the human prostate, bladder base, bladder neck, prostatic capsule and prostatic urethra. Blockade of these alpha-1 adrenoreceptors can cause smooth muscle in these tissues to relax, resulting in an improvement in urine flow and a reduction in BPH symptoms.
\n \n
\n \n
\n \n
\n \n \n
\nPresentation:
\nSiloflo 4 Capsule: Each capsule contains Silodosin INN 4 mg. Siloflo 8 Capsule: Each capsule contains Silodosin INN 8 mg.
\n \n \n
\nIndication:
\nSilodosin is indicated for the treatment of the signs and symptoms of Benign Prostatic Hyperplasia (BPH).
\n \n \n
\nDosage & Administration:
\n8 mg capsules taken orally once daily with a meal. 4 mg capsules taken orally once daily with a meal for those with moderate renal impairment [Creatinine Clearance (CCr) 30-50 mL/min].
\n \n \n
\nContrainidications:
\nPatients with severe renal & hepatic impairment, concomitant administration with strong Cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ketoconazole, clarithromycin, itraconazole, ritonavir) and patients with a history of hypersensitivity to Silodosin.
\n \n \n
\nWarning & Precautions:
\n- Postural hypotension with or without symptoms (e.g. dizziness) may develop when beginning Silodosin treatment - Silodosin should not be used in combination with other alpha-blockers - Inform patients planning cataract surgery to notify their ophthalmologist that they are taking Silodosin because of the possibility of Intraoperative Floppy Iris Syndrome (IFIS)
\n \n \n
\nSide effects:
\nMost common adverse reactions are retrograde ejaculation, dizziness, diarrhea, orthostatic hypotension, headache, nasopharyngitis and nasal congestion.
\n \n \n
\nDrug interaction:
\nStrong P-glycoprotein inhibitors (e.g., cyclosporine): Co-administration may increase plasma Silodosin concentration. Concomitant use of PDE5 inhibitors with alpha-blockers including Silodosin can potentially cause symptomatic hypotension.
\n \n \n
\nUse in special groups:
\nPregnancy: Silodosin is not indicated for use in women. Pediatric patients: Silodosin is not indicated for use in pediatric patients. Renal impairment: Silodosin should be reduced to 4 mg per day in patients with moderate renal impairment. Silodosin is contraindicated in patients with severe renal impairment. Hepatic impairment: No dosing adjustment is required in patients with mild or moderate hepatic impairment. Silodosin is contraindicated in patients with severe hepatic impairment.
\n \n \n
\nPacking:
\nSiloflo 4 Capsule: Each box contains 20 capsules in alu-alu blister pack. Siloflo 8 Capsule: Each box contains 20 capsules in alu-alu blister pack.
\nReviews:
No Review
Releted Products
